Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 2, 2022Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo
-
Jun 1, 2022Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA
-
May 17, 2022Data to be shared across multiple tumor types, including multiple myeloma, lung cancer and breast cancer
-
May 15, 2022Latest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomide
-
Apr 21, 2022*Results demonstrate strong, but not universal, correlation between organ clinical responses and clinically meaningful improvements in patient-reported outcomes from a pooled analysis of ROCKstar and KD025-208 clinical trials
-
Apr 14, 2022Results published today in the New England Journal of Medicine showed that treatment with rilzabrutinib resulted in a rapid and durable increase in platelet count in patients with heavily pretreated immune thrombocytopenia (ITP)
-
Apr 4, 2022If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
-
Mar 26, 2022Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions
-
Mar 9, 2022Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection)
-
Feb 26, 2022Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with eosinophilic esophagitis
-
Feb 26, 2022In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines
-
Feb 24, 2022Preclinical findings showed that tolebrutinib, among the investigational BTK inhibitors tested, had the best combination of brain penetration and potency that reinforces its potential to impact neuroinflammation
-
Feb 24, 2022-Company resubmits Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals to the U.S. Food and Drug Administration (FDA)-
-
Feb 10, 2022If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children
-
Feb 4, 2022Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD)
-
Feb 1, 2022Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria
-
Jan 27, 2022- Company to Host Conference Call Tomorrow, January 28th at 8:00 AM ET -
-
Jan 20, 2022- PRV-3279 is Designed to Intercept B-Cell Mediated Autoimmune Diseases -
-
Jan 19, 2022Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions
-
Dec 20, 2021
-
Dec 13, 2021Dupixent significantly improved skin clearance and reduced overall disease severity and itch in a Pivotal trial that met all primary and secondary endpoints
-
Dec 11, 2021Sarclisa combination therapy is first to demonstrate superiority to standard of care lenalidomide, bortezomib and dexamethasone (RVd) in a Phase 3 trial
-
Dec 8, 2021Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma
-
Nov 30, 2021* Regardless of gender or sexual orientation, employees welcoming a child into their family receive equal amount of paid time off